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Introduction 
Tetrahydrobiopterin (BH4) deficiency leads to an im-
paired function of phenylalanine (Phe), tyrosine (Tyr) 
and tryptophan hydroxylases. Consequent hyper-
phenylalaninemia and dopamine and serotonin defi-
ciency are the main metabolic disturbances on which 
depend the patient's symptoms and poor prognosis, 
irrespective of the enzyme defect causing impaired 
BH4 synthesis or regeneration. Three inborn errors 
of pterin metabolism are so far known: guanosine 
triphosphate cyclohydrolase (GTP CH I, EC 3.5.4.16) 
and 6-pyruvoyl tetrahydropterin synthase (6-PPH4S, 
Mc Kusick 26164) deficiency inhibit BH4 biosyn-
thesis, and dihydropteridine reductase (DHPR, EC 
1.66.99.7) deficiency prevents BH4 from being recy-
cled after oxidation in the hydroxylating reaction (1). 
The goals of the treatment are to control the hyper-
phenylalaninemia and to restore the homeostasis of 
neurotransmitters. In synthesis defects, hyperphenyl-
alaninemia can be easily corrected by BH4 adminis-
tration, while in D H P R deficiency Phe dietary restric-
tion is generally applied. With the exception of some 
milder cases, where BH4 monotherapy or just dietary 
treatment is affordable, most patients need hydroxy-
lated neurotransmitter precursor administration in 
addition to an inhibitor of peripheral aromatic amino 
acid decarboxylases to avoid clinical symptoms and 
to increase brain neurotransmitter levels (2). 
Enzymes: dihydropteridine reductase (EC 1.66.99.7) 
guanosine triphosphate cyclohydrolase (EC 3.5.4.16) 
6-pyruvoyl tetrahydropterin synthase (Mc Kusick 26164) 
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The comparison of the biochemical picture in BH4 
deficient patients at diagnosis with that observed at 
the time of optimal clinical response to therapy can 
be helpful in cases whose clinical monitoring is not 
sufficient to evaluate the adequacy of treatment. 
Case Report and Methods 
Three patients suffering from 6-PPH4S deficiency and 
three patients suffering from D H P R deficiency have 
been examined in two opposite conditions: at diag-
nosis, when hyperphenylalaninemia and biogenic 
amine deficiency symptoms were present, and during 
the follow up, when the hyperphenylalaninemia was 
controlled and symptoms disappeared (Table 1). As 
for the treatment, the 6-PPH4S deficient patients were 
on free diet but received a single daily dose of 5 mg/ 
kg synthetic BH4, while the D H P R deficient patients 
were given a Phe-restricted diet adjusted to the indi-
vidual tolerance. Both types of patients needed neu-
rotransmitter substitutive therapy in three daily di-
vided doses (L-dopa: 5 — 6 mg/kg; 5-OH-tryptophan: 
4 — 5 mg/kg; Carbidopa: 1 mg/kg). 
Serum, urine, and cerebrospinal fluid (CSF) samples 
were taken in the morning after midnight semifasting 
at diagnosis, and, when patients were on therapy, half 
way between two successive drug administrations. 
Serum Phe and Tyr were measured chromatographi-
cally with a Kromakon 500 automatic analyzer. 
Serum, urine and CSF neopterin (N) and biopterin 
(B) were measured by HPLC after oxidation with 
manganese dioxide and subsequent deproteinization 
with trichloroacetic acid; 5-hydroxyindolacetic acid 
14 Spada et a!.: Monitoring treatment in BH4 deficiency 
Table 1. Biochemical findings in 6 tetrahydrobiopterin (BH4) deficient patients, 3 suffering f rom 6-pyruvoyl tetrahydropterin 
synthase (6-PPH4S) and 3 f rom dihydropteridine reductase ( D H P R ) deficiency. Each patient was evaluated at diagnosis, prior to 
treatment, and when a good clinical response to the therapy had been obtained. 
Age Treatment Serum Urine CSF 
Patients 
BH4 diet N T Phe Tyr Ν Β N B N B H VA 5-HIAA 
(μπιοΙ/L) (nmol/L) (mmol/mol C) (nmol/1) 
1. 6-PPH4S 7 d — — 1589 34 43 0 28 0 449 0 34 13 
4.5 y + — + 70 46 1.3 12.6 1.4 2.4 115 2.1 288 162 
2. 6-PPH4S 5 m _ — — 743 52 61 0 27 0 206 6 70 21 
4 y + — + 32 68 4.5 19 2.3 1.7 124 5.5 283 202 
3. 6-PPH4S 11 m _ — _ 1282 45 229 0 13.4 0 215 9.7 91 15 
8 y + — + 161 66 4.6 9.2 1.7 1.3 77 13.7 349 120 
I. D H P R 14 m _ — — 1458 66 17 98 2.8 13.8 17 61 71 14 
6.5 y — + + 57 72 17 28 1.1 3.1 18 41 123 65 
II. D H P R 14 m — — 553 41 24 100 2 6.5 11 57 81 23 
2 y — + + 55 51 18 32 1 2.8 20 42 233 164 
III. D H P R 1 m — _ — 1993 42 17 35 12.6 9.3 47 117 59 4 
3 y — + + 61 69 35 28 0.8 1.2 16 37 168 125 
Controls 
31 30 12 5 1.1 0.5 9 10 250 110 
91 147 24 13 4 3 20 34 880 360 
N T = neurotransmitter precursors; Ν — neopterin; Β = biopterin; C = creatinine; HVA = homovanillic acid; 5-HIAA 
= 5-hydroxyindolacetic acid 
(5-HIAA) and homovanillic acid (HVA) were meas-
ured by HPLC with an ESA Coulochem 5100 A 
electrochemical detector (3). 
Results and Discussion 
Results are summarized in Table 1. As previously 
reported (4), high serum Phe levels are a limiting 
factor in the response to neurotransmitter precursor 
therapy, by interfering with their membrane transport 
or metabolism, and so altering the dose-effect rela-
tionships. Normal serum Phe levels are easily attained 
in synthesis defects by small doses of synthetic cofac-
tor, while D H P R deficient patients need a strict die-
tary control. This strategy allows to reduce the dose 
of neurotransmitter precursors, as well as to avoid 
most of the clinical fluctuations in symptomatology. 
In practice, the patient's individual optimal dosage is 
judged on a clinical basis, with only the monitoring 
of serum Phe concentration. Unfortunately, dopamine 
and serotonin can produce agonist and antagonist 
effects, and side effects, which can also mimic the 
symptoms of deficiency (4). As a consequence, the 
direct analysis of neurotransmitter metabolites in CSF 
might be necessary in some cases to evaluate the 
adequacy of treatment. 
Since reference parameters of pterin and neurotrans-
mitter metabolism in treated BH4 deficient patients 
are very scarce in literature, the present investigation 
offers new insights into the biochemical expression of 
a favourable outcome. The administration of BH4 
and the restriction of Phe dietary intake, respectively 
applied in 6-PPH4S and in D H P R deficiency, are both 
able to correct significantly the pattern of pterin me-
tabolism at the peripheral level, with only minor mod-
ifications of Β and Ν concentrations in CSF (Table 
1). Particularly, the urinary pattern of pterin excretion 
appears to be almost normalized, and this is the 
reason why the analysis of urinary pterins can miss 
the diagnosis of D H P R deficiency when serum Phe is 
low (5). 
The concentration of CSF neurotransmitter metabo-
lites, extremely low prior to hydroxylated precursors 
administration, increased only up to the lowest nor-
mal values on therapy. These findings show that in 
BH4 deficient patients a good clinical result is 
achieved at CSF biogenic amine levels below those of 
age-matched controls. In addition to the low dosage 
of neurotransmitter precursors required, as compared 
to other conditions such as Parkinson's disease (2), 
these data suggest that synaptic receptors are very 
sensitive in these patients, and that the attempt to 
reach therapeutically higher values of CSF neuro-
transmitter metabolites may result in overdose symp-
toms. 
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